Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gene Therapeutics & RNAiGene Therapy

PUBLISHER: Visiongain | PRODUCT CODE: 1869557

Cover Image

PUBLISHER: Visiongain | PRODUCT CODE: 1869557

Gene Therapy R&D Market Report 2025-2035

PUBLISHED:
PAGES: 357 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5829
PDF (Team License - Up to 6 Users)
USD 6901
PDF (Site License)
USD 8107
PDF (Enterprise License - Includes Free Datasets)
USD 10244.30

Add to Cart

Description

Table of Contents

List of Tables

The global Gene Therapy R&D market is projected to grow at a CAGR of 30.9% by 2035.

The Gene Therapy R&D Market Report 2025-2035 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Robust Gene Therapy Pipeline to Boost Growth

Cell and gene therapies (CGTs) are increasingly moving from the research labs to the clinic, owing to the fact that they target particular disease rather than the limited targets of small-molecule therapies. Both methods of therapy aim to introduce healthy cells or correct genetic defects in patients. Cancer is the primary area of interest and nearly half of all cell & gene therapies in clinical trials. CAR-T therapy (Chimeric Antigen Receptors), which combines cell & gene therapy, is one promising cancer treatment. CAR-T therapy takes a patient's immune cells and modifies their DNA to make them respond against cancer cells. The patient's immune system is reintroduced with modified gene cells, allowing immune system to battle the cancer.

The FDA has already given its approval to two CAR-T therapies. When no other treatment options were working, these therapies benefited some cancer patients. With further research activities, these therapies may become more widely available & capable of treating a wider variety of cancers. The registered clinical trials in Q1 2025 were reported to be 2,155 as compared to 2,093 in Q1 2024. Oncology and rare diseases remained the top areas of gene therapy development in both the overall pipeline (preclinical to pre-registration) and in the clinic (Phase I to pre-registration)

Development for rare diseases most commonly occurred in oncology, representing a majority of 52% compared to non-oncology rare disease gene therapy pipeline development

What would be the Impact of US Trade Tariffs on the Global Gene Therapy R&D Market?

The recent expansion of U.S. trade tariffs on pharmaceutical and biotechnological imports is expected to increase operational costs for gene therapy developers. As many critical materials, reagents, and specialised instruments used in R&D are sourced internationally, these tariffs could lead to supply chain disruptions, longer lead times, and higher procurement expenses. Smaller research organisations and academic groups may be most affected, as they have limited flexibility to absorb additional costs. Over time, this may encourage greater localisation of production, as companies seek to mitigate exposure to tariff risks by establishing domestic manufacturing and sourcing capabilities. While such measures could strengthen regional resilience, they also risk fragmenting global collaboration networks that have been vital to innovation in gene therapy research and development.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the gene therapy R&D market evolving?
  • What is driving and restraining the gene therapy R&D market?
  • How will each gene therapy R&D submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
  • How will the market shares for each gene therapy R&D submarket develop from 2025 to 2035?
  • What will be the main driver for the overall market from 2025 to 2035?
  • Will leading gene therapy R&D markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the gene therapy R&D projects for these leading companies?
  • How will the industry evolve during the period between 2025 and 2035? What are the implications of
  • gene therapy R&D projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the gene therapy R&D market?
  • Where is the gene therapy R&D market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Gene Therapy R&D market today, and over the next 10 years:

  • Our 357-page report provides 155 tables and 185 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
  • Forecasts to 2035 and other analyses reveal commercial prospects
  • In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

Segments Covered in the Report

  • Disease
  • Cancer
  • Rare Diseases
  • Cardiovascular Diseases
  • Ophthalmic Diseases
  • Haematology
  • Neurological
  • Diabetes Mellitus
  • Other Diseases
  • Vector
  • Viral
  • Retrovirus
  • Adenovirus
  • AAV
  • Lentivirus
  • Others
  • Non-viral
  • Naked DNA
  • Gene Gun
  • Electroporation
  • Lipofection
  • Techniques
  • Gene Augmentation Therapy
  • Gene Replacement Therapy
  • Participants
  • Small/Medium Pharma & Biotech
  • Universities & Research Institutes
  • Hospitals, Government & Public Bodies
  • Big Pharma

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • South East Asia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • MEA
  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles for some of the leading companies in the Gene Therapy R&D Market, 2025 to 2035, with a focus on this segment of these companies' operations.

  • Leading companies and the potential for market growth
  • American Gene Technologies
  • Applied Genetic
  • Astellas Pharma Inc.
  • Bayer
  • Benitec BioPharma
  • Biogen
  • Bluebird Bio
  • Bristol Myers Squibb
  • Calimmune, Inc. (CSL Behiring)
  • Cellectis
  • GenSight Biologics
  • Gilead Lifesciences, Inc.
  • GQ Bio Therapeutics GmbH (Pacira Pharmaceuticals, Inc.)
  • Novartis AG
  • OCUGEN, INC.
  • Orchard Therapeutics
  • Oxford Biomedica
  • Pfizer, Inc.
  • REGENXBIO Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi
  • Sarepta Therapeutics, Inc.
  • Spark Therapeutics (Subsidiary of Roche)
  • Takeda Pharmaceutical Company Limited
  • Taysha GTx
  • Transgene
  • UniQure N. V.
  • VeonGen Therapeutics
  • Voyager Therapeutics Inc.

Overall world revenue for Gene Therapy R&D Market, 2025 to 2035 in terms of value the market will surpass US$3,500 million in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

  • How will the Gene Therapy R&D Market, 2025 to 2035 report help you?
  • In summary, our 350+ page report provides you with the following knowledge:
  • Revenue forecasts to 2035 for Gene Therapy R&D Market 2025 to 2035, with forecasts for Disease, Vector, Techniques, and Participants, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2035 for five regional and 22 key national markets - See forecasts for the Gene Therapy R&D Market, 2025 to 2035 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 29 of the major companies involved in the Gene Therapy R&D Market, 2025 to 2035.
  • Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
  • Information found nowhere else
  • With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Gene Therapy R&D Market 2025 to 2035, market-leading companies. You will find data, trends and predictions.
Show more
Product Code: PHA1358

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Gene Therapy R&D Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Robust Gene Therapy Pipeline to Boost Growth
      • 3.2.1.2 Technological Advancements to Fuel Market Growth
      • 3.2.1.3 Role of Artificial Intelligence and Machine Learning in Gene Therapy
      • 3.2.1.4 Increasing Financing and Acquisitions by Major Players
      • 3.2.1.5 Growing Prevalence of Targeted Diseases Treatment
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Cell & Gene Therapies Target Specific Diseases
      • 3.2.2.2 High Cost to Stifle Gene Therapy R&D Growth
      • 3.2.2.3 Regulatory Scenarios to Challenge Industry Growth
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Growing Number of Clinical Trials to Offer Lucrative Growth Opportunities
      • 3.2.3.2 Expansion of Clinical Trials and CAR-T Therapies
      • 3.2.3.3 Facility Expansion Anticipated to Offer Lucrative Growth Prospects
      • 3.2.3.4 Artificial Intelligence Can Bring Value to Gene Therapy R&D
  • 3.1 U.S. Tariffs: What's the Impact on Global Gene Therapy R&D Market?
    • 3.1.1 Overview
    • 3.1.2 V-Shaped Recovery Scenario
    • 3.1.3 Why V-Shaped Recovery?
      • 3.1.3.1 Impact from Tariffs
      • 3.1.3.2 Market Dynamics and Demand Recovery
      • 3.1.3.3 Policy and Funding Support
      • 3.1.3.4 Timeframe for Recovery
    • 3.1.4 U-Shaped Recovery Scenario
      • 3.1.4.1 Why U-Shaped Recovery?
      • 3.1.4.2 Impact from Tariffs
      • 3.1.4.3 Market Dynamics and Demand Recovery
      • 3.1.4.4 Policy and Funding Support
      • 3.1.4.5 Timeframe for Recovery
    • 3.1.5 L Shaped Recovery Scenario
      • 3.1.5.1 Why L-Shaped Recovery?
      • 3.1.5.2 Impact from Tariffs
      • 3.1.5.3 Market Dynamics and Demand Recovery
      • 3.1.5.4 Policy and Funding Support
      • 3.1.5.5 Timeframe for Recovery
    • 3.1.6 What Strategic Considerations Should Clients Factor into Their Near-term (2025-2030) and Long-term (2025-2035) Planning?
    • 3.1.7 Impact of U.S. and China Trade War on Gene Therapy R&D Market
    • 3.1.8 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
  • 3.2 Porter's Five Forces Analysis
    • 3.2.1 Bargaining Power of Suppliers
    • 3.2.2 Bargaining Power of Buyers
    • 3.2.3 Competitive Rivalry
    • 3.2.4 Threat of Substitute Products
    • 3.2.5 Threat of New Entrants
  • 3.3 PEST Analysis
    • 3.3.1 Political Factors Impacting Gene Therapy R&D Market
    • 3.3.2 Economic Factors Impacting Gene Therapy R&D Market
    • 3.3.3 Social Factors Impacting Gene Therapy R&D Market
    • 3.3.4 Technological Factors Impacting Gene Therapy R&D Market

4 Gene Therapy R&D Market Analysis by Disease

  • 4.1 Key Findings
  • 4.2 Disease Segment: Market Attractiveness Index
  • 4.3 Gene Therapy R&D Market Size Estimation and Forecast by Disease
  • 4.4 Cancer
    • 4.4.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
    • 4.4.2 Market Share by Region, 2025 & 2035 (%)
  • 4.5 Rare Diseases
    • 4.5.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
    • 4.5.2 Market Share by Region, 2025 & 2035 (%)
    • 4.5.3 Rare Diseases Market Size Estimation and Forecast by Type
      • 4.5.3.1 Oncologic
      • 4.5.3.2 Non-oncologic
  • 4.6 Cardiovascular Diseases
    • 4.6.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
    • 4.6.2 Market Share by Region, 2025 & 2035 (%)
  • 4.7 Ophthalmic Diseases
    • 4.7.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
    • 4.7.2 Market Share by Region, 2025 & 2035 (%)
  • 4.8 Haematology
    • 4.8.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
    • 4.8.2 Market Share by Region, 2025 & 2035 (%)
  • 4.9 Neurological
    • 4.9.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
    • 4.9.2 Market Share by Region, 2025 & 2035 (%)
  • 4.10 Diabetes Mellitus
    • 4.10.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
    • 4.10.2 Market Share by Region, 2025 & 2035 (%)
  • 4.11 Other Diseases
    • 4.11.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
    • 4.11.2 Market Share by Region, 2025 & 2035 (%)

5 Gene Therapy R&D Market Analysis by Vector

  • 5.1 Key Findings
  • 5.2 Vector Segment: Market Attractiveness Index
  • 5.3 Gene Therapy R&D Market Size Estimation and Forecast by Vector
  • 5.4 Viral
    • 5.4.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
    • 5.4.2 Market Share by Region, 2025 & 2035 (%)
    • 5.4.3 Viral Vector Market Size Estimation and Forecast by Type
      • 5.4.3.1 Retrovirus
      • 5.4.3.2 Adenovirus
      • 5.4.3.3 AAV
      • 5.4.3.4 Lentivirus
      • 5.4.3.5 Others
  • 5.5 Non-viral
    • 5.5.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
    • 5.5.2 Market Share by Region, 2025 & 2035 (%)
    • 5.5.3 Non-viral Vector Market Size Estimation and Forecast by Type
      • 5.5.3.1 Naked DNA
      • 5.5.3.2 Gene Gun
      • 5.5.3.3 Electroporation
      • 5.5.3.4 Lipofection

6 Gene Therapy R&D Market Analysis by Techniques

  • 6.1 Key Findings
  • 6.2 Techniques Segment: Market Attractiveness Index
  • 6.3 Gene Therapy R&D Market Size Estimation and Forecast by Techniques
  • 6.4 Gene Augmentation Therapy
    • 6.4.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
    • 6.4.2 Market Share by Region, 2025 & 2035 (%)
  • 6.5 Gene Replacement Therapy
    • 6.5.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
    • 6.5.2 Market Share by Region, 2025 & 2035 (%)

7 Gene Therapy R&D Market Analysis by Participants

  • 7.1 Key Findings
  • 7.2 Participants Segment: Market Attractiveness Index
  • 7.3 Gene Therapy R&D Market Size Estimation and Forecast by Participants
  • 7.4 Small/Medium Pharma & Biotech
    • 7.4.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
    • 7.4.2 Market Share by Region, 2025 & 2035 (%)
  • 7.5 Universities & Research Institutes
    • 7.5.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
    • 7.5.2 Market Share by Region, 2025 & 2035 (%)
  • 7.6 Hospitals, Government & Public Bodies
    • 7.6.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
    • 7.6.2 Market Share by Region, 2025 & 2035 (%)
  • 7.7 Big Pharma
    • 7.7.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
    • 7.7.2 Market Share by Region, 2025 & 2035 (%)

8 Gene Therapy R&D Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Gene Therapy R&D Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Gene Therapy R&D Market Attractiveness Index
  • 9.3 North America Gene Therapy R&D Market by Country, 2025, 2030 & 2035 (US$ Million)
  • 9.4 North America Gene Therapy R&D Market Size Estimation and Forecast by Country
  • 9.5 North America Gene Therapy R&D Market Size Estimation and Forecast by Disease
  • 9.6 North America Gene Therapy R&D Market Size Estimation and Forecast by Vector
  • 9.7 North America Gene Therapy R&D Market Size Estimation and Forecast by Techniques
  • 9.8 North America Gene Therapy R&D Market Size Estimation and Forecast by Participants
  • 9.9 U.S. Gene Therapy R&D Market Analysis
  • 9.10 Canada Gene Therapy R&D Market Analysis

10 Europe Gene Therapy R&D Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Gene Therapy R&D Market Attractiveness Index
  • 10.3 Europe Gene Therapy R&D Market by Country, 2025, 2030 & 2035 (US$ Million)
  • 10.4 Europe Gene Therapy R&D Market Size Estimation and Forecast by Country
  • 10.5 Europe Gene Therapy R&D Market Size Estimation and Forecast by Disease
  • 10.6 Europe Gene Therapy R&D Market Size Estimation and Forecast by Vector
  • 10.7 Europe Gene Therapy R&D Market Size Estimation and Forecast by Techniques
  • 10.8 Europe Gene Therapy R&D Market Size Estimation and Forecast by Participants
  • 10.9 Germany Gene Therapy R&D Market Analysis
  • 10.10 UK Gene Therapy R&D Market Analysis
  • 10.11 France Gene Therapy R&D Market Analysis
  • 10.12 Italy Gene Therapy R&D Market Analysis
  • 10.13 Spain Gene Therapy R&D Market Analysis
  • 10.14 Russia Gene Therapy R&D Market Analysis
  • 10.15 Rest of Europe Gene Therapy R&D Market Analysis

11 Asia Pacific Gene Therapy R&D Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Gene Therapy R&D Market Attractiveness Index
  • 11.3 Asia Pacific Gene Therapy R&D Market by Country, 2025, 2030 & 2035 (US$ Million)
  • 11.4 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Disease
  • 11.6 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Vector
  • 11.7 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Techniques
  • 11.8 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Participants
  • 11.9 Japan Gene Therapy R&D Market Analysis
  • 11.10 China Gene Therapy R&D Market Analysis
  • 11.11 India Gene Therapy R&D Market Analysis
  • 11.12 Australia Gene Therapy R&D Market Analysis
  • 11.13 South Korea Gene Therapy R&D Market Analysis
  • 11.14 South East Asia Gene Therapy R&D Market Analysis
  • 11.15 Rest of Asia Pacific Gene Therapy R&D Market Analysis

12 Latin America Gene Therapy R&D Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Gene Therapy R&D Market Attractiveness Index
  • 12.3 Latin America Gene Therapy R&D Market by Country, 2025, 2030 & 2035 (US$ Million)
  • 12.4 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Country
  • 12.5 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Disease
  • 12.6 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Vector
  • 12.7 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Techniques
  • 12.8 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Participants
  • 12.9 Brazil Gene Therapy R&D Market Analysis
  • 12.10 Mexico Gene Therapy R&D Market Analysis
  • 12.11 Rest of Latin America Gene Therapy R&D Market Analysis

13 MEA Gene Therapy R&D Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Gene Therapy R&D Market Attractiveness Index
  • 13.3 MEA Gene Therapy R&D Market by Country, 2025, 2030 & 2035 (US$ Million)
  • 13.4 MEA Gene Therapy R&D Market Size Estimation and Forecast by Country
  • 13.5 MEA Gene Therapy R&D Market Size Estimation and Forecast by Disease
  • 13.6 MEA Gene Therapy R&D Market Size Estimation and Forecast by Vector
  • 13.7 MEA Gene Therapy R&D Market Size Estimation and Forecast by Techniques
  • 13.8 MEA Gene Therapy R&D Market Size Estimation and Forecast by Participants
  • 13.9 GCC Gene Therapy R&D Market Analysis
  • 13.10 South Africa Gene Therapy R&D Market Analysis
  • 13.11 Rest of MEA Gene Therapy R&D Market Analysis

14 Company Profiles

  • 14.1 Astellas Pharma Inc.
    • 14.1.1 Company Snapshot
    • 14.1.2 Company Overview
    • 14.1.3 Financial Analysis
      • 14.1.3.1 Net Revenue, 2015-2024
      • 14.1.3.2 R&D, 2020-2024
    • 14.1.4 Product Benchmarking
  • 14.2 American Gene Technologies
    • 14.2.1 Company Snapshot
    • 14.2.2 Company Overview
    • 14.2.3 Product Benchmarking
  • 14.3 Beacon Therapeutics
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Product Benchmarking
    • 14.3.4 Strategic Outlook
  • 14.4 Bayer
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
      • 14.4.3.1 Net Revenue, 2020-2024
      • 14.4.3.2 R&D, 2020-2024
    • 14.4.4 Product Benchmarking
    • 14.4.5 Strategic Outlook
  • 14.5 Benitec BioPharma
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Product Benchmarking
  • 14.6 Biogen
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Net Revenue, 2020-2024
      • 14.6.3.2 Regional Market Shares, 2024
      • 14.6.3.3 R&D, 2020-2024
    • 14.6.4 Product Benchmarking
    • 14.6.5 Strategic Outlook
  • 14.7 Bluebird Bio
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Financial Analysis
      • 14.7.3.1 Net Revenue, 2020-2024
      • 14.7.3.2 R&D, 2020-2024
    • 14.7.4 Product Benchmarking
    • 14.7.5 Strategic Outlook
  • 14.8 Bristol Myers Squibb
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Financial Analysis
      • 14.8.3.1 Net Revenue, 2020-2024
      • 14.8.3.2 Regional Market Shares, 2024
      • 14.8.3.3 R&D, 2020-2024
    • 14.8.4 Product Benchmarking
    • 14.8.5 Strategic Outlook
  • 14.9 Calimmune, Inc. (CSL Behiring)
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Product Benchmarking
    • 14.9.4 Strategic Outlook
  • 14.10 Cellectis
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Net Revenue, 2020-2024
      • 14.10.3.2 R&D, 2020-2024
    • 14.10.4 Product Benchmarking
  • 14.11 GenSight Biologics
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Product Benchmarking
  • 14.12 Gilead Lifesciences, Inc.
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Net Revenue, 2020-2024
      • 14.12.3.2 R&D, 2020-2024
    • 14.12.4 Product Benchmarking
  • 14.13 Novartis AG
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Financial Analysis
      • 14.13.3.1 Net Revenue, 2020-2024
      • 14.13.3.2 Regional Market Shares, 2024
      • 14.13.3.3 R&D, 2020-2024
    • 14.13.4 Product Benchmarking
    • 14.13.5 Strategic Outlook
  • 14.14 Orchard Therapeutics
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Product Benchmarking
  • 14.15 Oxford Biomedica
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Financial Analysis
      • 14.15.3.1 Net Revenue, 2020-2024
      • 14.15.3.2 R&D, 2020-2024
    • 14.15.4 Product Benchmarking
    • 14.15.5 Strategic Outlook
  • 14.16 Pfizer, Inc.
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Financial Analysis
      • 14.16.3.1 Net Revenue, 2020-2024
      • 14.16.3.2 Regional Market Shares, 2024
      • 14.16.3.3 R&D, 2020-2024
    • 14.16.4 Product Benchmarking
    • 14.16.5 Strategic Outlook
  • 14.17 REGENXBIO Inc.
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Financial Analysis
      • 14.17.3.1 Net Revenue, 2020-2024
      • 14.17.3.2 R&D, 2020-2024
    • 14.17.4 Product Benchmarking
    • 14.17.5 Strategic Outlook
  • 14.18 Sangamo Therapeutics, Inc.
    • 14.18.1 Company Snapshot
    • 14.18.2 Company Overview
    • 14.18.3 Financial Analysis
      • 14.18.3.1 Net Revenue, 2020-2024
      • 14.18.3.2 R&D, 2020-2024
    • 14.18.4 Product Benchmarking
    • 14.18.5 Strategic Outlook
  • 14.19 Sanofi
    • 14.19.1 Company Snapshot
    • 14.19.2 Company Overview
    • 14.19.3 Financial Analysis
      • 14.19.3.1 Net Revenue, 2020-2024
      • 14.19.3.2 Regional Market Shares, 2024
      • 14.19.3.3 R&D, 2020-2024
    • 14.19.4 Product Benchmarking
    • 14.19.5 Strategic Outlook
  • 14.20 Spark Therapeutics (Subsidiary of Roche)
    • 14.20.1 Company Snapshot
    • 14.20.2 Company Overview
    • 14.20.3 Product Benchmarking
  • 14.21 Takeda Pharmaceutical Company Limited
    • 14.21.1 Company Snapshot
    • 14.21.2 Company Overview
    • 14.21.3 Financial Analysis
      • 14.21.3.1 Net Revenue, 2020-2024
      • 14.21.3.2 R&D, 2020-2024
    • 14.21.4 Product Benchmarking
  • 14.22 Transgene
    • 14.22.1 Company Snapshot
    • 14.22.2 Company Overview
    • 14.22.3 Product Benchmarking
  • 14.23 UniQure NV
    • 14.23.1 Company Snapshot
    • 14.23.2 Company Overview
    • 14.23.3 Financial Analysis
      • 14.23.3.1 Net Revenue, 2020-2024
      • 14.23.3.2 R&D, 2020-2024
    • 14.23.4 Product Benchmarking
    • 14.23.5 Strategic Outlook
  • 14.24 Voyager Therapeutics Inc.
    • 14.24.1 Company Snapshot
    • 14.24.2 Company Overview
    • 14.24.3 Financial Analysis
      • 14.24.3.1 Net Revenue, 2020-2024
      • 14.24.3.2 R&D, 2020-2024
    • 14.24.4 Product Benchmarking
    • 14.24.5 Strategic Outlook
  • 14.25 VeonGen Therapeutics
    • 14.25.1 Company Snapshot
    • 14.25.2 Company Overview
    • 14.25.3 Product Benchmarking
    • 14.25.4 Strategic Outlook
  • 14.26 GQ Bio Therapeutics GmbH (Pacira Pharmaceuticals, Inc.)
    • 14.26.1 Company Snapshot
    • 14.26.2 Company Overview
    • 14.26.3 Product Benchmarking
    • 14.26.4 Strategic Outlook
  • 14.27 OCUGEN, INC.
    • 14.27.1 Company Snapshot
    • 14.27.2 Company Overview
    • 14.27.3 Product Benchmarking
    • 14.27.4 Strategic Outlook
  • 14.28 Taysha GTx
    • 14.28.1 Company Snapshot
    • 14.28.2 Company Overview
    • 14.28.3 Product Benchmarking
  • 14.29 Sarepta Therapeutics, Inc.
    • 14.29.1 Company Snapshot
    • 14.29.2 Company Overview
    • 14.29.3 Product Benchmarking
    • 14.29.4 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players

List of Other Companies Mentioned in the Report

Show more
Product Code: PHA1358

List of Tables

  • Table 1 Gene Therapy R&D Market Snapshot, 2025 & 2035 (US$ Million, CAGR %)
  • Table 2 Gene Therapies in Pre-registration as of Q2 2025
  • Table 3 Cell and Gene Therapy Landscape
  • Table 4 Approved Gene, Cell, and RNA Therapies for Clinical Use
  • Table 5 Key Technologies in Gene Therapy R&D
  • Table 6 Cell and Gene Therapy Landscape
  • Table 7 Cell and Gene Therapy Funding Landscape
  • Table 8 Global Cell & Gene Therapy Landscape, 2025
  • Table 9 Global Gene Therapy R&D Market Forecast by Region, 2025-2035 (US$ mn, AGR%, CAGR%): 'V' Shaped Recovery
  • Table 10 Global Gene Therapy R&D Market Forecast by Region, 2025-2035 (US$ mn, AGR%, CAGR%): 'U' Shaped Recovery
  • Table 11 Global Gene Therapy R&D Market Forecast by Region, 2025-2035 (US$ mn, AGR%, CAGR%): 'L' Shaped Recovery
  • Table 12 Gene Therapy R&D Market Forecast by Disease, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 13 Cancer Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
  • Table 14 Rare Diseases Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
  • Table 15 Gene Therapy R&D Market Forecast by Rare Diseases, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 16 Cardiovascular Diseases Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
  • Table 17 Ophthalmic Diseases Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
  • Table 18 Haematology Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
  • Table 19 Neurological Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
  • Table 20 Diabetes Mellitus Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
  • Table 21 Other Diseases Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
  • Table 22 Gene Therapy R&D Market Forecast by Vector, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 23 Viral Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
  • Table 24 Gene Therapy R&D Market Forecast by Viral Vector, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 25 Non-viral Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
  • Table 26 Gene Therapy R&D Market Forecast by Non-viral, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 27 Gene Therapy R&D Market Forecast by Techniques, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 28 Gene Augmentation Therapy Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
  • Table 29 Gene Replacement Therapy Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR%, CAGR%)
  • Table 30 Gene Therapy R&D Market Forecast by Participants, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 31 Small/Medium Pharma & Biotech Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 32 Universities Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 33 Hospitals, Government & Public Bodies Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 34 Big Pharma Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 35 Global Gene Therapy R&D Market Forecast by Region, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 36 North America Gene Therapy R&D Market Forecast by Disease, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 37 North America Gene Therapy R&D Market Forecast by Vector, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 38 North America Gene Therapy R&D Market Forecast by Techniques, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 39 North America Gene Therapy R&D Market Forecast by Participants, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 40 U.S. Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 41 Canada Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 42 Europe Gene Therapy R&D Market Forecast by Country, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 43 Europe Gene Therapy R&D Market Forecast by Disease, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 44 Europe Gene Therapy R&D Market Forecast by Vector, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 45 Europe Gene Therapy R&D Market Forecast by Techniques, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 46 Europe Gene Therapy R&D Market Forecast by Participants, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 47 Germany Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 48 UK Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 49 France Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 50 Italy Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 51 Spain Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 52 Russia Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 53 Rest of Europe Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 54 Asia Pacific Gene Therapy R&D Market Forecast by Country, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 55 Asia Pacific Gene Therapy R&D Market Forecast by Disease, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 56 Asia Pacific Gene Therapy R&D Market Forecast by Vector, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 57 Asia Pacific Gene Therapy R&D Market Forecast by Techniques, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 58 Asia Pacific Gene Therapy R&D Market Forecast by Participants, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 59 Japan Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 60 China Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 61 India Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 62 Australia Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 63 South Korea Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 64 South East Asia Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 65 Rest of Asia Pacific Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 66 Latin America Gene Therapy R&D Market Forecast by Country, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 67 Latin America Gene Therapy R&D Market Forecast by Disease, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 68 Latin America Gene Therapy R&D Market Forecast by Vector, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 69 Latin America Gene Therapy R&D Market Forecast by Techniques, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 70 Latin America Gene Therapy R&D Market Forecast by Participants, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 71 Brazil Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 72 Mexico Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 73 Rest of Latin America Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 74 MEA Gene Therapy R&D Market Forecast by Country, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 75 MEA Gene Therapy R&D Market Forecast by Disease, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 76 MEA Gene Therapy R&D Market Forecast by Vector, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 77 MEA Gene Therapy R&D Market Forecast by Techniques, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 78 MEA Gene Therapy R&D Market Forecast by Participants, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 79 GCC Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 80 South Africa Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 81 Rest of MEA Gene Therapy R&D Market Forecast, 2025-2035 (US$ mn, AGR%, CAGR%)
  • Table 82 Astellas Pharma Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 83 Astellas Pharma Inc.: Product Benchmarking
  • Table 84 American Gene Technologies: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 85 American Gene Technologies: Product Benchmarking
  • Table 86 Beacon Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 87 Beacon Therapeutics: Product Benchmarking
  • Table 88 Beacon Therapeutics: Strategic Outlook
  • Table 89 Bayer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 90 Bayer: Product Benchmarking
  • Table 91 Bayer: Strategic Outlook
  • Table 92 Benitec BioPharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 93 Benitec BioPharma: Product Benchmarking
  • Table 94 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 95 Biogen: Product Benchmarking
  • Table 96 Biogen: Strategic Outlook
  • Table 97 Bluebird Bio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 98 Bluebird Bio: Product Benchmarking
  • Table 99 Bluebird Bio: Strategic Outlook
  • Table 100 Bristol Myers Squibb: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 101 Bristol Myers Squibb: Product Benchmarking
  • Table 102 Bristol Myers Squibb: Strategic Outlook
  • Table 103 Calimmune, Inc. (CSL Behiring): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 104 Calimmune, Inc. (CSL Behiring): Product Benchmarking
  • Table 105 Calimmune, Inc. (CSL Behiring): Strategic Outlook
  • Table 106 Cellectis: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 107 Cellectis: Product Benchmarking
  • Table 108 GenSight Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 109 GenSight Biologics: Product Benchmarking
  • Table 110 Gilead Lifesciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 111 Gilead Lifesciences, Inc.: Product Benchmarking
  • Table 112 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 113 Novartis AG: Product Benchmarking
  • Table 114 Novartis AG: Strategic Outlook
  • Table 115 Orchard Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 116 Orchard Therapeutics: Product Benchmarking
  • Table 117 Oxford Biomedica: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 118 Oxford Biomedica: Product Benchmarking
  • Table 119 Oxford Biomedica: Strategic Outlook
  • Table 120 Pfizer, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 121 Pfizer, Inc.: Product Benchmarking
  • Table 122 Pfizer, Inc.: Strategic Outlook
  • Table 123 REGENXBIO Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 124 REGENXBIO Inc.: Product Benchmarking
  • Table 125 REGENXBIO Inc.: Strategic Outlook
  • Table 126 Sangamo Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 127 Sangamo Therapeutics, Inc.: Product Benchmarking
  • Table 128 Sangamo Therapeutics, Inc.: Strategic Outlook
  • Table 129 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 130 Sanofi: Product Benchmarking
  • Table 131 Sanofi: Strategic Outlook
  • Table 132 Spark Therapeutics (Subsidiary of Roche): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 133 Spark Therapeutics (Subsidiary of Roche): Product Benchmarking
  • Table 134 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 135 Takeda Pharmaceutical Company Limited: Product Benchmarking
  • Table 136 Transgene: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 137 Transgene: Product Benchmarking
  • Table 138 UniQure NV: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 139 UniQure NV: Product Benchmarking
  • Table 140 UniQure NV: Strategic Outlook
  • Table 141 Voyager Therapeutics Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 142 Voyager Therapeutics Inc.: Product Benchmarking
  • Table 143 Voyager Therapeutics Inc.: Strategic Outlook
  • Table 144 VeonGen Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 145 VeonGen Therapeutics: Product Benchmarking
  • Table 146 VeonGen Therapeutics: Strategic Outlook
  • Table 147 GQ Bio Therapeutics GmbH (Pacira Pharmaceuticals, Inc.): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 148 GQ Bio Therapeutics GmbH (Pacira Pharmaceuticals, Inc.): Product Benchmarking
  • Table 149 GQ Bio Therapeutics GmbH (Pacira Pharmaceuticals, Inc.): Strategic Outlook
  • Table 150 OCUGEN, INC.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 151 OCUGEN, INC.: Product Benchmarking
  • Table 152 OCUGEN, INC.: Strategic Outlook
  • Table 153 Taysha GTx: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 154 Taysha GTx: Product Benchmarking
  • Table 155 Sarepta Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 156 Sarepta Therapeutics, Inc.: Product Benchmarking
  • Table 157 Sarepta Therapeutics, Inc.: Strategic Outlook

List of Figures

  • Figure 1 Gene Therapy R&D Market Segmentation
  • Figure 2 Gene Therapy R&D Market by Disease: Market Attractiveness Index
  • Figure 3 Gene Therapy R&D Market by Vector: Market Attractiveness Index
  • Figure 4 Gene Therapy R&D Market by Techniques: Market Attractiveness Index
  • Figure 5 Gene Therapy R&D Market by Participants: Market Attractiveness Index
  • Figure 6 Gene Therapy R&D Market Attractiveness Index by Region
  • Figure 7 Gene Therapy R&D Market: Market Dynamics
  • Figure 8 Number of Therapies from Preclinical Through Pre-registration till April 2025
  • Figure 9 Total Number of Deals by Type
  • Figure 10 Volume and Dollar Value of Series A and Seed Financings for Gene, Cell, & RNA Therapy Companies
  • Figure 1 Gene Therapy R&D Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: V-Shaped Recovery Scenario
  • Figure 2 Gene Therapy R&D Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: U-Shaped Recovery Scenario
  • Figure 3 Gene Therapy R&D Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: L-Shaped Recovery Scenario
  • Figure 4 Short Term & Long Term Planning
  • Figure 5 Impact of U.S. and China Trade War
  • Figure 6 Most Impacted Countries
  • Figure 7 Gene Therapy R&D Market: Porter's Five Forces Analysis
  • Figure 8 Gene Therapy R&D Market: PEST Analysis
  • Figure 9 Gene Therapy R&D Market Attractiveness Index by Disease
  • Figure 10 Gene Therapy R&D Market Forecast by Disease, 2025-2035 (US$ Million, AGR %)
  • Figure 11 Gene Therapy R&D Market Share Forecast by Disease, 2025, 2030, 2035 (%)
  • Figure 12 Cancer Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
  • Figure 13 Cancer Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 14 Rare Diseases Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
  • Figure 15 Rare Diseases Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 16 Gene Therapy R&D Market Forecast by Rare Diseases, 2025-2035 (US$ Million, AGR %)
  • Figure 17 Gene Therapy R&D Market by Rare Diseases, 2025, 2030 & 2035 (%)
  • Figure 18 Cardiovascular Diseases Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
  • Figure 19 Cardiovascular Diseases Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 20 Ophthalmic Diseases Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
  • Figure 21 Ophthalmic Diseases Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 22 Hematology Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
  • Figure 23 Hematology Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 24 Neurological Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
  • Figure 25 Neurological Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 26 Diabetes Mellitus Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
  • Figure 27 Diabetes Mellitus Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 28 Other Diseases Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
  • Figure 29 Other Diseases Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 30 Gene Therapy R&D Market Attractiveness Index by Disease
  • Figure 31 Gene Therapy R&D Market Forecast by Vector, 2025-2035 (US$ Million, AGR %)
  • Figure 32 Gene Therapy R&D Market Share Forecast by Vector, 2025, 2030, 2035 (%)
  • Figure 33 Viral Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
  • Figure 34 Viral Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 35 Gene Therapy R&D Market Forecast by Viral Vector, 2025-2035 (US$ Million, AGR %)
  • Figure 36 Gene Therapy R&D Market by Viral Vector, 2025, 2030 & 2035 (%)
  • Figure 37 Non-viral Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
  • Figure 38 Non-viral Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 39 Gene Therapy R&D Market Forecast by Non-viral Vector, 2025-2035 (US$ Million, AGR %)
  • Figure 40 Gene Therapy R&D Market by Non-viral Vector, 2025, 2030 & 2035 (%)
  • Figure 41 Gene Therapy R&D Market Attractiveness Index by Techniques
  • Figure 42 Gene Therapy R&D Market Forecast by Techniques, 2025-2035 (US$ Million, AGR %)
  • Figure 43 Gene Therapy R&D Market Share Forecast by Techniques, 2025, 2030, 2035 (%)
  • Figure 44 Gene Augmentation Therapy Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
  • Figure 45 Gene Augmentation Therapy Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 46 Gene Replacement Therapy Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
  • Figure 47 Gene Replacement Therapy Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 48 Gene Therapy R&D Market Attractiveness Index by Participants
  • Figure 49 Gene Therapy R&D Market Forecast by Participants, 2025-2035 (US$ Million, AGR %)
  • Figure 50 Gene Therapy R&D Market Share Forecast by Participants, 2025, 2030, 2035 (%)
  • Figure 51 Small/Medium Pharma & Biotech Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
  • Figure 52 Small/Medium Pharma & Biotech Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 53 Universities & Research Institutes Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
  • Figure 54 Universities & Research Institutes Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 55 Hospitals, Government & Public Bodies Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
  • Figure 56 Hospitals, Government & Public Bodies Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 57 Big Pharma Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
  • Figure 58 Big Pharma Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 59 Gene Therapy R&D Market Forecast by Region 2025, 2030, 2035 (Revenue, CAGR%)
  • Figure 60 Gene Therapy R&D Market Share Forecast by Region 2025, 2030, 2035 (%)
  • Figure 61 Gene Therapy R&D Market by Region, 2025-2035 (US$ Mn)
  • Figure 62 North America Gene Therapy R&D Market Attractiveness Index
  • Figure 63 North America Gene Therapy R&D Market by Country, 2025, 2030 & 2035 (US$ Million)
  • Figure 64 North America Gene Therapy R&D Market Forecast by Country, 2025-2035 (US$ Million, AGR %)
  • Figure 65 North America Gene Therapy R&D Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 66 North America Gene Therapy R&D Market Forecast by Disease, 2025-2035 (US$ Million, AGR %)
  • Figure 67 North America Gene Therapy R&D Market Share Forecast by Disease, 2025 & 2035 (%)
  • Figure 68 North America Gene Therapy R&D Market Forecast by Vector, 2025-2035 (US$ Million, AGR %)
  • Figure 69 North America Gene Therapy R&D Market Share Forecast by Vector, 2025 & 2035 (%)
  • Figure 70 North America Gene Therapy R&D Market Forecast by Techniques, 2025-2035 (US$ Million, AGR %)
  • Figure 71 North America Gene Therapy R&D Market Share Forecast by Techniques, 2025 & 2035 (%)
  • Figure 72 North America Gene Therapy R&D Market Forecast by Participants, 2025-2035 (US$ Million, AGR %)
  • Figure 73 North America Gene Therapy R&D Market Share Forecast by Participants, 2025 & 2035 (%)
  • Figure 74 U.S. Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 75 Canada Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 76 Europe Gene Therapy R&D Market Attractiveness Index
  • Figure 77 Europe Gene Therapy R&D Market by Country, 2025, 2030 & 2035 (US$ Million)
  • Figure 78 Europe Gene Therapy R&D Market Forecast by Country, 2025-2035 (US$ Million, AGR %)
  • Figure 79 Europe Gene Therapy R&D Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 80 Europe Gene Therapy R&D Market Forecast by Disease, 2025-2035 (US$ Million, AGR %)
  • Figure 81 Europe Gene Therapy R&D Market Share Forecast by Disease, 2025 & 2035 (%)
  • Figure 82 Europe Gene Therapy R&D Market Forecast by Vector, 2025-2035 (US$ Million, AGR %)
  • Figure 83 Europe Gene Therapy R&D Market Share Forecast by Vector, 2025 & 2035 (%)
  • Figure 84 Europe Gene Therapy R&D Market Forecast by Techniques, 2025-2035 (US$ Million, AGR %)
  • Figure 85 Europe Gene Therapy R&D Market Share Forecast by Techniques, 2025 & 2035 (%)
  • Figure 86 Europe Gene Therapy R&D Market Forecast by Participants, 2025-2035 (US$ Million, AGR %)
  • Figure 87 Europe Gene Therapy R&D Market Share Forecast by Participants, 2025 & 2035 (%)
  • Figure 88 Germany Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 89 UK Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 90 France Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 91 Italy Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 92 Spain Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 93 Russia Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 94 Rest of Europe Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 95 Asia Pacific Gene Therapy R&D Market Attractiveness Index
  • Figure 96 Asia Pacific Gene Therapy R&D Market by Country, 2025, 2030 & 2035 (US$ Million)
  • Figure 97 Asia Pacific Gene Therapy R&D Market Forecast by Country, 2025-2035 (US$ Million, AGR %)
  • Figure 98 Asia Pacific Gene Therapy R&D Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 99 Asia Pacific Gene Therapy R&D Market Forecast by Disease, 2025-2035 (US$ Million, AGR %)
  • Figure 100 Asia Pacific Gene Therapy R&D Market Share Forecast by Disease, 2025 & 2035 (%)
  • Figure 101 Asia Pacific Gene Therapy R&D Market Forecast by Vector, 2025-2035 (US$ Million, AGR %)
  • Figure 102 Asia Pacific Gene Therapy R&D Market Share Forecast by Vector, 2025 & 2035 (%)
  • Figure 103 Asia Pacific Gene Therapy R&D Market Forecast by Techniques, 2025-2035 (US$ Million, AGR %)
  • Figure 104 Asia Pacific Gene Therapy R&D Market Share Forecast by Techniques, 2025 & 2035 (%)
  • Figure 105 Asia Pacific Gene Therapy R&D Market Forecast by Participants, 2025-2035 (US$ Million, AGR %)
  • Figure 106 Asia Pacific Gene Therapy R&D Market Share Forecast by Participants, 2025 & 2035 (%)
  • Figure 107 Japan Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 108 China Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 109 India Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 110 Australia Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 111 South Korea Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 112 South East Asia Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 113 Rest of Asia Pacific Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 114 Latin America Gene Therapy R&D Market Attractiveness Index
  • Figure 115 Latin America Gene Therapy R&D Market by Country, 2025, 2030 & 2035 (US$ Million)
  • Figure 116 Latin America Gene Therapy R&D Market Forecast by Country, 2025-2035 (US$ Million, AGR %)
  • Figure 117 Latin America Gene Therapy R&D Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 118 Latin America Gene Therapy R&D Market Forecast by Disease, 2025-2035 (US$ Million, AGR %)
  • Figure 119 Latin America Gene Therapy R&D Market Share Forecast by Disease, 2025 & 2035 (%)
  • Figure 120 Latin America Gene Therapy R&D Market Forecast by Vector, 2025-2035 (US$ Million, AGR %)
  • Figure 121 Latin America Gene Therapy R&D Market Share Forecast by Vector, 2025 & 2035 (%)
  • Figure 122 Latin America Gene Therapy R&D Market Forecast by Techniques, 2025-2035 (US$ Million, AGR %)
  • Figure 123 Latin America Gene Therapy R&D Market Share Forecast by Techniques, 2025 & 2035 (%)
  • Figure 124 Latin America Gene Therapy R&D Market Forecast by Participants, 2025-2035 (US$ Million, AGR %)
  • Figure 125 Latin America Gene Therapy R&D Market Share Forecast by Participants, 2025 & 2035 (%)
  • Figure 126 Brazil Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 127 Mexico Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 128 Rest of Latin America Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 129 MEA Gene Therapy R&D Market Attractiveness Index
  • Figure 130 MEA Gene Therapy R&D Market by Country, 2025, 2030 & 2035 (US$ Million)
  • Figure 131 MEA Gene Therapy R&D Market Forecast by Country, 2025-2035 (US$ Million, AGR %)
  • Figure 132 MEA Gene Therapy R&D Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 133 MEA Gene Therapy R&D Market Forecast by Disease, 2025-2035 (US$ Million, AGR %)
  • Figure 134 MEA Gene Therapy R&D Market Share Forecast by Disease, 2025 & 2035 (%)
  • Figure 135 MEA Gene Therapy R&D Market Forecast by Vector, 2025-2035 (US$ Million, AGR %)
  • Figure 136 MEA Gene Therapy R&D Market Share Forecast by Vector, 2025 & 2035 (%)
  • Figure 137 MEA Gene Therapy R&D Market Forecast by Techniques, 2025-2035 (US$ Million, AGR %)
  • Figure 138 MEA Gene Therapy R&D Market Share Forecast by Techniques, 2025 & 2035 (%)
  • Figure 139 MEA Gene Therapy R&D Market Forecast by Participants, 2025-2035 (US$ Million, AGR %)
  • Figure 140 MEA Gene Therapy R&D Market Share Forecast by Participants, 2025 & 2035 (%)
  • Figure 141 GCC Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 142 South Africa Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 143 Rest of MEA Gene Therapy R&D Market Forecast, 2025-2035 (US$ Million, AGR %)
  • Figure 144 Astellas Pharma Inc.: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 145 Astellas Pharma Inc.: R&D, 2020-2024 (US$ Million, AGR %)
  • Figure 146 Bayer: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 147 Bayer: R&D, 2020-2024 (US$ million, AGR %)
  • Figure 148 Biogen: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 149 Biogen: Regional Market Shares (%), 2024
  • Figure 150 Biogen: R&D, 2020-2024 (US$ Million, AGR %)
  • Figure 151 Bluebird Bio: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 152 Bluebird Bio: R&D, 2020-2024 (US$ Million, AGR %)
  • Figure 153 Bristol Myers Squibb: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 154 Bristol Myers Squibb: Regional Market Shares (%), 2024
  • Figure 155 Bristol Myers Squibb: R&D, 2020-2024 (US$ Million, AGR %)
  • Figure 156 Cellectis: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 157 Cellectis: R&D, 2020-2024 (US$ Million, AGR %)
  • Figure 158 Gilead Lifesciences, Inc.: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 159 Gilead Lifesciences, Inc.: R&D, 2020-2024 (US$ Million, AGR %)
  • Figure 160 Novartis AG: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 161 Novartis AG: Regional Market Shares, 2024
  • Figure 162 Novartis AG: R&D, 2020-2024 (US$ million, AGR %)
  • Figure 163 Oxford Biomedica: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 164 Oxford Biomedica: R&D, 2020-2024 (US$ Million, AGR %)
  • Figure 165 Pfizer, Inc.: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 166 Pfizer, Inc.: Regional Market Shares (%), 2024
  • Figure 167 Pfizer, Inc.: R&D, 2020-2024 (US$ Million, AGR %)
  • Figure 168 REGENXBIO Inc.: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 169 REGENXBIO Inc.: R&D, 2020-2024 (US$ Million, AGR %)
  • Figure 170 Sangamo Therapeutics, Inc.: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 171 Sangamo Therapeutics, Inc.: R&D, 2020-2024 (US$ Million, AGR %)
  • Figure 172 Sanofi: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 173 Sanofi: Regional Market Shares (%), 2024
  • Figure 174 Sanofi: R&D, 2020-2024 (US$ Million, AGR %)
  • Figure 175 Takeda Pharmaceutical Company Limited: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 176 Takeda Pharmaceutical Company Limited: R&D, 2020-2024 (US$ Million, AGR %)
  • Figure 177 UniQure NV: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 178 UniQure NV: R&D, 2020-2024 (US$ Million, AGR %)
  • Figure 179 Voyager Therapeutics Inc.: Net Revenue, 2020-2024 (US$ Million, AGR %)
  • Figure 180 Voyager Therapeutics Inc.: R&D, 2020-2024 (US$ Million, AGR %)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!